Drugs Made In America Acquisition Corp

Research Drugs Made In America Acquisition Corp (DMAA) on Bullrun: valuation model: 14.7% undervalued, market cap USD 258.06M, P/E 53.6. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerDMAA
• ExchangeNASDAQ
• CountryUnited States
• SectorFinancial Services
• IndustryShell Companies
• CurrencyUSD
• Valuation signal14.7% undervalued
• Market capUSD 258.06M
• P/E53.6
• Financial periodFY2025
• Net incomeUSD 5.94M

Valuation Snapshot

Bullrun's latest valuation model marks Drugs Made In America Acquisition Corp as 14.7% undervalued; latest market cap is USD 258.06M; P/E is 53.6.

About Drugs Made In America Acquisition Corp

Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.

Frequently asked questions

Is Drugs Made In America Acquisition Corp overvalued or undervalued?

Bullrun's valuation model currently marks Drugs Made In America Acquisition Corp as 14.7% undervalued.

What is Drugs Made In America Acquisition Corp's market cap?

Drugs Made In America Acquisition Corp's market capitalization is USD 258.06M.

What is Drugs Made In America Acquisition Corp's P/E ratio?

Drugs Made In America Acquisition Corp's price-to-earnings (P/E) ratio is 53.6.

What does Drugs Made In America Acquisition Corp do?

Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp.